New genetic markers for transplant rejection

In cardiovascular, respiratory, kidney and haematological diseases transplantation remains the most effective long term therapy for patients with advanced organ failure. In addition, hematopoietic stem cell transplantation (HSCT) for the treatment of lymphoproliferative disorders and leukemias has recently become an important mainstay in oncology. There is an urgent need for non-invasive, predictive and diagnostic monitoring to improve outcomes. The global market for transplant diagnostics is projected to grow at 12% CAGR to reach $553 million in 2015.

Further Information: PDF

MBM ScienceBridge GmbH
Phone: (0551) 30724-151

Contact
Dr. Jens-Peter Horst

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Targeted Printing

Single-cell technology… Bright prospects for personalized medicine: Experts from the Fraunhofer Institute for Microengineering and Microsystems IMM harness their know-how in microfluidics and single-cell technologies to print organ structures. They…

Cobalt-copper tandem converts carbon dioxide to ethanol

Positioning cobalt and copper in close proximity on an electrode facilitates selective conversion of the greenhouse gas CO₂ to ethanol / Prime example of sustainable chemical research. The continuing release…

How To Replace PFAS

Hardly any other chemical substance can compete with PFAS, due to their unique properties. That explains why it is so hard to find a replacement for these toxic “forever chemicals”,…